Overview

Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)

Status:
Completed
Trial end date:
2012-12-24
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of initial treatment with sitagliptin and metformin in patients with type 2 diabetes mellitus in China. The primary hypothesis is that after 24 weeks, initial co-administration treatment with sitagliptin and metformin provided greater reduction in hemoglobin A1C (A1C) compared to initial treatment with sitagliptin alone and with metformin alone.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Metformin
Sitagliptin Phosphate